515 related articles for article (PubMed ID: 19027730)
1. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
2. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
3. Adenosine 5'-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model.
Ningaraj NS; Rao MK; Black KL
Cancer Res; 2003 Dec; 63(24):8899-911. PubMed ID: 14695207
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Hu J; Ljubimova JY; Inoue S; Konda B; Patil R; Ding H; Espinoza A; Wawrowsky KA; Patil C; Ljubimov AV; Black KL
PLoS One; 2010 Apr; 5(4):e10108. PubMed ID: 20419092
[TBL] [Abstract][Full Text] [Related]
5. Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models.
Black KL; Yin D; Konda BM; Wang X; Hu J; Ko MK; Bayan JA; Sacapano MR; Espinoza AJ; Ong JM; Irvin D; Shu Y
Brain Res; 2008 Aug; 1227():198-206. PubMed ID: 18602898
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
7. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
10. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Lefranc F; James S; Camby I; Gaussin JF; Darro F; Brotchi J; Gabius J; Kiss R
J Neurosurg; 2005 Apr; 102(4):706-14. PubMed ID: 15871514
[TBL] [Abstract][Full Text] [Related]
11. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
12. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
13. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
14. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Yokosawa M; Sonoda Y; Sugiyama S; Saito R; Yamashita Y; Nishihara M; Satoh T; Kumabe T; Yokoyama M; Tominaga T
Tohoku J Exp Med; 2010 Aug; 221(4):257-64. PubMed ID: 20622491
[TBL] [Abstract][Full Text] [Related]
15. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Pyrko P; Schönthal AH; Hofman FM; Chen TC; Lee AS
Cancer Res; 2007 Oct; 67(20):9809-16. PubMed ID: 17942911
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Gupta V; Su YS; Wang W; Kardosh A; Liebes LF; Hofman FM; Schönthal AH; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E20. PubMed ID: 16709026
[TBL] [Abstract][Full Text] [Related]
17. Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.
Ramalho MJ; Sevin E; Gosselet F; Lima J; Coelho MAN; Loureiro JA; Pereira MC
Int J Pharm; 2018 Jul; 545(1-2):84-92. PubMed ID: 29715532
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Liu HL; Huang CY; Chen JY; Wang HY; Chen PY; Wei KC
PLoS One; 2014; 9(12):e114311. PubMed ID: 25490097
[TBL] [Abstract][Full Text] [Related]
19. Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway.
Gu YT; Xue YX; Wang YF; Wang JH; Chen X; ShangGuan QR; Lian Y; Zhong L; Meng YN
Neuropharmacology; 2013 Dec; 75():407-15. PubMed ID: 23973310
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR
Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
